Retrospective Study
Copyright ©The Author(s) 2023.
World J Clin Cases. Nov 26, 2023; 11(33): 7994-8002
Published online Nov 26, 2023. doi: 10.12998/wjcc.v11.i33.7994
Table 1 Clinical characteristics of patients with primary breast diffuse large B-cell lymphoma
VariableValue
No. of patients32
Age (yr)mean ± SD: 56.6 ± 12.4; Range: 32-78
SexFemale: 28 (87.5%); Male: 4 (12.5%)
Tumor size (cm)mean ± SD: 4.2 ± 2.1; Range: 1.5-9
Treatment modalitiesChemotherapy alone: 8 (25%); Chemotherapy + rituximab: 16 (50%); Chemotherapy + radiotherapy: 6 (18.8%); Chemotherapy + rituximab + radiotherapy: 2 (6.3%)
Ki-67 expression level (%)Mean ± SD: 68.4 ± 21.6; Range: 20-95
Follow-up duration (mo)Median: 24; Range: 6-60
Survival statusDead: 8 (25%); Alive with disease: 6 (18.8%); Alive without disease: 18 (56.3%)